We are pleased to provide shareholders with a new corporate strategy update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene’s commercial partnering and collaboration potential.

The lead clinical focus is on investigating anti-cancer, plus cardio-protective and FTO properties in metastatic breast cancer, using the peripherally administered bisantrene formulation, RC220 with a view to improving therapeutic outcomes and heart health for patients with cancer.

The secondary focus is on pursuing increased anti-cancer / FTO benefits of bisantrene combined with current standard of care therapies in acute myeloid leukaemia (AML).

Video update, presentation and shareholder information sessions will be available to provide additional background and offer Q&A opportunities.

Start the conversation! Ask Race Oncology a question about this announcement in the 'Ask a Question' section below.